You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Novartis’ canakinumab fails to improve overall survival in lung cancer trial

Novartis has announced that its interleukin-1beta (IL-1β) inhibitor canakinumab failed to hit the primary endpoint of overall survival in a Phase III non-small cell lung cancer (NSCLC) trial.